STAT2 Mouse Monoclonal Antibody [Clone ID: 19G8.H2.H6]

Specifications

Product Data
Clone Name	19G8.H2.H6
Applications	IHC, WB
Recommend Dilution	ELISA: 1:5,000 - 1:10,000, WB: 1:1000, IHC: 1:2.5 ug/mL
Reactivity	Human, Mouse
Host	Mouse
Clonality	Monoclonal
Immunogen	This monoclonal antibody was produced by repeated immunizations with a synthetic peptide corresponding to residues near the carboxy terminus of mouse STAT2 protein.
Formulation	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Concentration	lot specific
Conjugation	Unconjugated
Storage Condition	Store at -20°C as received.
Gene Name	signal transducer and activator of transcription 2
Database Link	NP_005410 Entrez Gene 20847 MouseEntrez Gene 6773 Human UniProt ID P52630
Synonyms	IMD44; ISGF-3; P113; STAT113
Note	STAT2 is a member of the STAT family of transcription factors. Unlike other STATs, STAT2 is unique as it can only be activated by interferons (IFNs). STAT2 is a critical component in mediating many IFN-stimulated biological activities including antiproliferation and antiviral responses. Upon IFN treatment, STAT1 and STAT2 become tyrosine phosphorylated, assemble as heterodimers that bind IRF9 to form the ISGF3 complex. This complex translocates to the nucleus, binds to promoters of IFN-stimulated genes and mediates gene transcription. Consequently, mutations in STAT2 or loss of STAT2 expression leads to impairment in IFN signal transduction and gene activation. IFN-alpha is an approved drug for the treatment of several forms of cancer. Yet only a subset of patients who receive IFN-alpha therapy benefit from the treatment. Given that STAT2 is activated by IFNs, it is important to define if the reduced or lack of antitumor effects seen in cancer patients on IFN therapy is due to in defects in STAT2 function. Our goal is to identify regions/motifs within the structural domains of STAT2 that not only are essential for the tyrosine phosphorylation of STAT2, but also regulate the antitumor effects of IFN-alpha. Collectively, the results of our studies will emphasize the physiological role of STAT2 in cancer. From a clinical viewpoint, cancer patients who may benefit the most from receiving IFN-alpha therapy can be selected based on their STAT2 function.
Reference Data
Protein Families	Druggable Genome, Transcription Factors
Protein Pathways	Chemokine signaling pathway, Jak-STAT signaling pathway

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.